High Risk Program
The Dubin Breast Center’s Cancer Risk Evaluation Program (CaRE) is dedicated to helping individuals who are at high risk for developing breast cancer. You may be at high risk for a variety of reasons, including genetic mutation or a personal or family history of cancer. The CaRE Program is affiliated with The Tisch Cancer Institute at Mount Sinai, The Mount Sinai Hospital, and the Icahn School of Medicine, which enables us to offer comprehensive services for risk assessment, cancer prevention, research, and education. Our program helps you understand, reduce, and manage your risk for developing breast cancer.
Who Is Eligible?
Individuals who are eligible for the CaRE Program include those who have:
- An inherited gene mutation (BRCA 1 or BRCA 2) or other syndrome
- A personal or significant family history of premenopausal breast or ovarian or male breast cancer
- A breast biopsy or surgery revealing lobular carcinoma in-situ or atypical hyperplasia
- A personal history of radiation therapy to the chest for lymphoma
Our Evaluation Process
After we carefully consider your medical and family history, we create a personalized cancer risk profile to help guide you as you make decisions about your care. We discuss all possible options for risk reduction, including close surveillance with regular clinical evaluation and examination, risk-reducing medications (chemoprevention), or preventive (prophylactic) surgery. We may also refer you for genetic counseling and possible testing.
Personalized, Multidisciplinary Care
If you are enrolled in the CaRE Program, you will receive accurate assessment of your individual risk for developing breast cancer along with comprehensive, personalized plans for reducing your breast cancer risk, based on the most up-to-date information available. You also benefit by having the best chance for early cancer detection, when treatment is generally most effective. Located within one of the world’s premiere academic medical centers, we can provide our patients with access to the latest advances in health care, including access to clinical research studies designed to develop novel preventive therapies for minimizing breast cancer risk.
Among the outstanding services offered at the Dubin Breast Center’s CaRE Program are:
- State-of-the-art breast cancer screening, including imaging with 3D mammography, ultrasound, and magnetic resonance imaging
- Expert pathology review by specialized breast pathologists for patients with previous biopsy or those requiring biopsy
- Prophylactic surgery
- Intensive follow-up with surveillance exams and coordination of imaging
- Genetic counseling and testing by certified genetic counselors
- Support programs to address the physical and emotional needs of individuals living with breast cancer risk
- Breast cancer prevention clinical research studies designed to develop novel therapies for reducing breast cancer risk.
- Consultation with medical oncologists and plastic surgeons when indicated
- Nutrition and lifestyle counseling for risk reduction, focused on diet, weight loss, and exercise
Dubin Breast Center Partners with BioMe to study Risk of Breast Cancer
We have designed the Cancer Risk Evaluation (CaRE) program for individuals at increased risk of breast cancer. Personalized risk management strategies may include high-intensity surveillance imaging, drug therapy to lower risk, or prophylactic surgery. We have partnered with the Charles Bronfman Institute for Personalized Medicine’s BioMe Biobank Program to employ genomics for greater understanding of your cancer risk. The goal is to gain a more precise determination of how risk factors vary among different groups of people. We expect this knowledge to lead to better personalized planning of how best to manage breast cancer risk. The BioMe Biobank Program, established in 2007, contains more than 315,000 DNA samples and more than 370,000 plasma samples (all stored without names) from approximately 33,000 Mount Sinai patients, as of October 2015. We have paired these samples with data from a questionnaire about activities of daily life and family medical history. Patients who agree to participate donate one blood sample, which allows us to isolate the DNA and conduct genotyping to analyze individual differences in sequence that may be important for cancer research in the future. We hope that this genomic discovery approach will also help us study breast cancer risk within distinct multi-ethnic populations. If you would like to participate in BioMe, ask your doctor, and our research staff will coordinate collection of a blood sample and questionnaire. Learn more